Current Understanding and Evidence Regarding Qiliqiangxin (QLQX) in Heart Failure Treatment: From Basic to Clinical Research

Le résumé fourni par la source

Qiliqiangxin (QLQX), a traditional Chinese medicine (TCM) formulation, has shown therapeutic potential in heart failure (HF) through its multifaceted mechanisms. This review synthesizes preclinical and clinical evidence, highlighting the ability of QLQX to modulate cardiac remodeling, inflammation, fibrosis, and neurohormonal activation. Preclinical studies have revealed that the bioactive components of QLQX target peroxisome proliferator-activated receptor γ, mitochondrial metabolism, and calcium transport. Clinically, QLQX capsule decreases N-terminal pro B-type natriuretic peptide levels and improves functional outcomes in chronic HF. The QUEST trial has indicated diminished cardiovascular mortality and hospitalization in patients with HF and reduced ejection fraction receiving QLQX treatment in addition to standard medication. Challenges include standardization of TCM formulations and mechanistic clarity. Future research should prioritize rigorous trials, comparative studies with conventional therapies, and integration of TCM into evidence-based practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.